54 related articles for article (PubMed ID: 21187487)
1. Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models.
Gamez I; Ryan RP; Keir ST
Anticancer Res; 2010 Dec; 30(12):5037-42. PubMed ID: 21187487
[TBL] [Abstract][Full Text] [Related]
2. Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models.
Gamez I; Ryan RP; Reid LD; Routt SM; Hollister BA
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1415-22. PubMed ID: 20809121
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
Yanagisawa M; Fujimoto-Ouchi K; Yorozu K; Yamashita Y; Mori K
Oncol Rep; 2009 Aug; 22(2):241-7. PubMed ID: 19578762
[TBL] [Abstract][Full Text] [Related]
4. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
[TBL] [Abstract][Full Text] [Related]
5. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
6. Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapy.
Fujimoto-Ouchi K; Sekiguchi F; Yamamoto K; Shirane M; Yamashita Y; Mori K
Cancer Chemother Pharmacol; 2010 Jul; 66(2):269-76. PubMed ID: 19904537
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
Fujita K; Sano D; Kimura M; Yamashita Y; Kawakami M; Ishiguro Y; Nishimura G; Matsuda H; Tsukuda M
Oncol Rep; 2007 Jul; 18(1):47-51. PubMed ID: 17549344
[TBL] [Abstract][Full Text] [Related]
8. Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.
Panickar KS
Curr Opin Mol Ther; 2010 Dec; 12(6):780-9. PubMed ID: 21154169
[TBL] [Abstract][Full Text] [Related]
9. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer.
Dredge K; Kink JA; Johnson RM; Bytheway I; Marton LJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):191-5. PubMed ID: 19685053
[TBL] [Abstract][Full Text] [Related]
10. Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models.
Zhong W; Hansen R; Li B; Cai Y; Salvador C; Moore GD; Yan J
J Immunother; 2009 Sep; 32(7):703-12. PubMed ID: 19561538
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models.
Fujimoto-Ouchi K; Sekiguchi F; Tanaka Y
Cancer Chemother Pharmacol; 2002 Mar; 49(3):211-6. PubMed ID: 11935213
[TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
13. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
14. Steroid-sparing effect of corticorelin acetate in peritumoral cerebral edema is associated with improvement in steroid-induced myopathy.
Recht L; Mechtler LL; Wong ET; O'Connor PC; Rodda BE
J Clin Oncol; 2013 Mar; 31(9):1182-7. PubMed ID: 23382470
[TBL] [Abstract][Full Text] [Related]
15. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: from bedside to bench.
Burkhardt JK; Hofstetter CP; Santillan A; Shin BJ; Foley CP; Ballon DJ; Pierre Gobin Y; Boockvar JA
J Clin Neurosci; 2012 Nov; 19(11):1568-72. PubMed ID: 22985932
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model.
Higgins B; Kolinsky K; Linn M; Adames V; Zhang YE; Moisa C; Dugan U; Heimbrook D; Packman K
Anticancer Res; 2007; 27(4B):2279-87. PubMed ID: 17695515
[TBL] [Abstract][Full Text] [Related]
18. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
[TBL] [Abstract][Full Text] [Related]
19. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y; Harada K; Ferdous T; Yoshida H
Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
[TBL] [Abstract][Full Text] [Related]
20. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]